DeepMind AlphaFold Veteran Raises $50M to Launch AI-Powered Protein Design Platform
核心洞察
Latent Labs (搜索), founded by former DeepMind (搜索) AlphaFold team co-lead Dr. Simon Kohl, emerges from stealth with $50M in total funding to develop AI foundation models for programmable biology.
The company's platform enables pharmaceutical partners to computationally design novel therapeutic proteins, including antibodies (搜索) and enzymes (搜索), with enhanced molecular properties for drug development.
The Series A funding round of $40M was co-led by Radical Ventures (搜索) and Sofinnova Partners (搜索), with participation from notable investors including Google (搜索) Chief Scientist Jeff Dean and industry veterans.
Latent Labs (搜索), a frontier artificial intelligence company focused on revolutionizing protein design, has emerged from stealth mode with $50 million in total funding. The company aims to transform drug discovery and development through advanced AI foundation models that make biology programmable.
The London and San Francisco-based company was founded by Dr. Simon Kohl, who previously served as co-lead of DeepMind (搜索)'s protein design team and was a senior research scientist on the Nobel Prize-winning AlphaFold2 project. This prestigious background brings significant expertise in applying AI to biological challenges.
Strategic Funding for AI-Powered Drug Discovery
The funding package includes a substantial $40 million Series A round, co-led by Radical Ventures (搜索) and Sofinnova Partners (搜索). Additional investors include Flying Fish, Isomer, and existing backers 8VC, Kindred Capital, and Pillar VC. The round also attracted prominent angel investors, including Google (搜索) Chief Scientist Jeff Dean, Transformer architecture inventor Aidan Gomez, and ElevenLabs founder Mati Staniszewski.
Advanced Platform for Therapeutic Protein Design
Building on the success of AlphaFold in solving protein structure prediction, Latent Labs (搜索) is taking the next crucial step by developing generative AI techniques for designing proteins from scratch. The platform enables researchers to computationally create new therapeutic molecules, including antibodies (搜索) and enzymes (搜索), potentially unlocking previously challenging drug targets.
"Every biotechnology or pharmaceutical company wants to be at the forefront of technology to find the best therapeutic molecules, yet not all are in a position to develop the most advanced AI models for the job," explained Dr. Simon Kohl, CEO and founder of Latent Labs (搜索). "That's where Latent Labs comes in. We push the frontiers of generative biology, giving our partners instant access to tools that accelerate their drug design programs."
Enhancing Drug Development Efficiency
The platform's capabilities extend beyond basic protein design, offering tools to optimize molecular features such as affinity and stability. These advancements promise to expedite drug development timelines and improve success rates in the pharmaceutical development process.
By providing pharmaceutical companies with access to cutting-edge AI tools for protein design, Latent Labs (搜索) aims to democratize access to advanced drug discovery technology while opening new pathways to personalized medicine development.